<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261975</url>
  </required_header>
  <id_info>
    <org_study_id>607</org_study_id>
    <nct_id>NCT01261975</nct_id>
  </id_info>
  <brief_title>Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System</brief_title>
  <official_title>Co-Axial Micro-incision Cataract Surgery(C-MICS) Versus Standard Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the hypothesis that the time to reach a stable
      refraction is significantly shorter in eyes operated with the 1.8 mm coaxial microincision
      compared to eyes operated with the 2.75 mm standard incision using the Stellaris Vision
      Enhancement System.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Refractive Stability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cumulative portion of eyes achieving refractive stability within 0.5 D of the final value for the remainder of the trial by surgical procedure and visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Visit 1, visit 2, visit 3, visit 4</time_frame>
    <description>Best corrected distance visual acuity(BCVA) was assessed using logMAR charts. Change from preoperative visit summarized by visit. A minus change represents an improvement of the visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>visit 5, visit 6, visit 7, visit 8</time_frame>
    <description>Best corrected distance visual acuity(BCVA) was assessed using logMAR charts. Change from baseline summarized by visit. A minus change represents an improvement of the visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>Visit 1, visit 2, visit 3, visit 4</time_frame>
    <description>Uncorrected visual acuity(UCVA) was assessed using logMAR charts. Change from baseline summarized by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>visit 5, visit 6, visit 7, visit 8</time_frame>
    <description>Uncorrected visual acuity(UCVA) was assessed using logMAR charts. Change from baseline summarized by visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgically Induced Astigmatism (SIA)</measure>
    <time_frame>Visits 1-3</time_frame>
    <description>Surgically induced astigmatism was presented in dioptres at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgically Induced Astigmatism (SIA)</measure>
    <time_frame>Visits 4-8</time_frame>
    <description>Surgically induced astigmatism presented in dioptres at each visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cataract</condition>
  <condition>Aphakia</condition>
  <arm_group>
    <arm_group_label>Coaxial Micro-Incision Cataract Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.8 mm coaxial microincision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coaxial Small Incision Cataract Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.75 mm standard incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coaxial Micro-Incision Cataract Surgery</intervention_name>
    <description>1.8 mm coaxial micro incision</description>
    <arm_group_label>Coaxial Micro-Incision Cataract Surgery</arm_group_label>
    <other_name>Stellaris Vision Enhancement System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coaxial Small Incision Cataract Surgery</intervention_name>
    <description>2.75 mm coaxial incision</description>
    <arm_group_label>Coaxial Small Incision Cataract Surgery</arm_group_label>
    <other_name>Stellaris Vision Enhancement System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be undergoing bilateral primary in-the-bag intraocular lens (IOL)
             implantation for the correction of aphakia.

          -  Subject's ocular media must be clear except for the presence of the cataract in both
             eyes.

        Exclusion Criteria:

          -  Subject with any disease, which, in the Investigator's opinion, might interfere with
             the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Williart, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <results_first_submitted>September 21, 2011</results_first_submitted>
  <results_first_submitted_qc>January 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2012</results_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Surgery</keyword>
  <keyword>Intraocular Lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at one clinical site in Europe. First participant was enrolled on 8/25/2009 and last participant exited the study on 4/27/2010. Study lasted six months for enrollment and three months for follow-up.</recruitment_details>
      <pre_assignment_details>36 participants at least 50 years of age were enrolled in bilateral cataract surgery with phacoemulsification and intraocular lens implantation for the correction of aphakia. The Stellaris Vision Enhancement System was used for a 1.8mm Coaxial Micro-Incision procedure in one eye and a 2.75mm coaxial standard procedure in the contralateral eye.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cataract Surgery</title>
          <description>Cataract surgery with phacoemulsification. Eligible patients were randomized to undergo cataract surgery using the 1.8 mm coaxial micro incision technique in either the right eye or the left eye. The fellow eye was assigned to undergo cataract surgery using the 2.75 mm standard incision. The Stellaris Vision Enhancement System was used for the surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36">36 Participants 72 eyes started</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35">35 Participants 70 eyes completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Surgical complication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cataract Surgery</title>
          <description>Cataract surgery with phacoemulsification using the Stellaris Vision Enhancement System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Aged 71 to 81 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Refractive Stability</title>
        <description>Cumulative portion of eyes achieving refractive stability within 0.5 D of the final value for the remainder of the trial by surgical procedure and visit.</description>
        <time_frame>12 weeks</time_frame>
        <population>Cumulative Proportion of Eyes Achieving Refractive Stability (within 0.5 D)— Full analysis Set (FAS) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Refractive Stability</title>
          <description>Cumulative portion of eyes achieving refractive stability within 0.5 D of the final value for the remainder of the trial by surgical procedure and visit.</description>
          <population>Cumulative Proportion of Eyes Achieving Refractive Stability (within 0.5 D)— Full analysis Set (FAS) Population</population>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Best corrected distance visual acuity(BCVA) was assessed using logMAR charts. Change from preoperative visit summarized by visit. A minus change represents an improvement of the visual acuity</description>
        <time_frame>Visit 1, visit 2, visit 3, visit 4</time_frame>
        <population>Best Corrected Distance Visual Acuity (logMAR), Change from baseline, FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <description>Best corrected distance visual acuity(BCVA) was assessed using logMAR charts. Change from preoperative visit summarized by visit. A minus change represents an improvement of the visual acuity</description>
          <population>Best Corrected Distance Visual Acuity (logMAR), Change from baseline, FAS Population</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.24"/>
                    <measurement group_id="O2" value="-0.27" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.22"/>
                    <measurement group_id="O2" value="-0.39" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.20"/>
                    <measurement group_id="O2" value="-0.38" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.24"/>
                    <measurement group_id="O2" value="-0.38" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Best corrected distance visual acuity(BCVA) was assessed using logMAR charts. Change from baseline summarized by visit. A minus change represents an improvement of the visual acuity.</description>
        <time_frame>visit 5, visit 6, visit 7, visit 8</time_frame>
        <population>Best Corrected Distance Visual Acuity (logMAR), change from baseline, FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <description>Best corrected distance visual acuity(BCVA) was assessed using logMAR charts. Change from baseline summarized by visit. A minus change represents an improvement of the visual acuity.</description>
          <population>Best Corrected Distance Visual Acuity (logMAR), change from baseline, FAS Population</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.22"/>
                    <measurement group_id="O2" value="-0.40" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.24"/>
                    <measurement group_id="O2" value="-0.42" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.24"/>
                    <measurement group_id="O2" value="-0.42" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.22"/>
                    <measurement group_id="O2" value="-0.41" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Visual Acuity</title>
        <description>Uncorrected visual acuity(UCVA) was assessed using logMAR charts. Change from baseline summarized by visit.</description>
        <time_frame>Visit 1, visit 2, visit 3, visit 4</time_frame>
        <population>Uncorrected Visual Acuity (logMAR), change from baseline, FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Visual Acuity</title>
          <description>Uncorrected visual acuity(UCVA) was assessed using logMAR charts. Change from baseline summarized by visit.</description>
          <population>Uncorrected Visual Acuity (logMAR), change from baseline, FAS Population</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.32"/>
                    <measurement group_id="O2" value="-0.34" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.29"/>
                    <measurement group_id="O2" value="-0.45" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.30"/>
                    <measurement group_id="O2" value="-0.41" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.30"/>
                    <measurement group_id="O2" value="-0.46" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Visual Acuity</title>
        <description>Uncorrected visual acuity(UCVA) was assessed using logMAR charts. Change from baseline summarized by visit.</description>
        <time_frame>visit 5, visit 6, visit 7, visit 8</time_frame>
        <population>Uncorrected Visual Acuity (logMAR), change from baseline, FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Visual Acuity</title>
          <description>Uncorrected visual acuity(UCVA) was assessed using logMAR charts. Change from baseline summarized by visit.</description>
          <population>Uncorrected Visual Acuity (logMAR), change from baseline, FAS Population</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.33"/>
                    <measurement group_id="O2" value="-0.48" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.31"/>
                    <measurement group_id="O2" value="-0.47" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.35"/>
                    <measurement group_id="O2" value="-0.49" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.31"/>
                    <measurement group_id="O2" value="-0.51" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgically Induced Astigmatism (SIA)</title>
        <description>Surgically induced astigmatism was presented in dioptres at each visit.</description>
        <time_frame>Visits 1-3</time_frame>
        <population>Surgically Induced Astigmatism, FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgically Induced Astigmatism (SIA)</title>
          <description>Surgically induced astigmatism was presented in dioptres at each visit.</description>
          <population>Surgically Induced Astigmatism, FAS Population</population>
          <units>Dioptres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.55"/>
                    <measurement group_id="O2" value="0.80" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.39"/>
                    <measurement group_id="O2" value="0.61" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.21"/>
                    <measurement group_id="O2" value="0.60" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgically Induced Astigmatism (SIA)</title>
        <description>Surgically induced astigmatism presented in dioptres at each visit.</description>
        <time_frame>Visits 4-8</time_frame>
        <population>Surgically Induced Astigmatism—FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Coaxial Micro-Incision Cataract Surgery</title>
            <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System</description>
          </group>
          <group group_id="O2">
            <title>Coaxial Small-Incision Cataract Surgery</title>
            <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgically Induced Astigmatism (SIA)</title>
          <description>Surgically induced astigmatism presented in dioptres at each visit.</description>
          <population>Surgically Induced Astigmatism—FAS Population</population>
          <units>Dioptres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.37"/>
                    <measurement group_id="O2" value="0.52" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.36"/>
                    <measurement group_id="O2" value="0.53" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.27"/>
                    <measurement group_id="O2" value="0.59" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.31"/>
                    <measurement group_id="O2" value="0.51" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.21"/>
                    <measurement group_id="O2" value="0.42" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <desc>Safety Set</desc>
      <group_list>
        <group group_id="E1">
          <title>Co-Axial Micro-Incision Cataract Surgery</title>
          <description>1.8 mm coaxial micro-incision cataract surgery (C-MICS) with phacoemulsification using the Stellaris Vision Enhancement System.</description>
        </group>
        <group group_id="E2">
          <title>Coaxial Small-Incision Cataract Surgery</title>
          <description>2.75 mm coaxial standard cataract surgical procedure with phacoemulsification using the Stellaris Vision Enhancement System.</description>
        </group>
        <group group_id="E3">
          <title>Cataract Surgery All Participants</title>
          <description>Events by participant one eye with 1.8 mm coaxial micro-incision cataract surgery (C-MICS) and the contralateral eye with the 2.75 mm coaxial standard cataract surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <description>Pre-existing condition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <description>Unrelated to study, crossed both arms, non ocular SAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Arthrosis</sub_title>
                <description>Unrelated to study, crossed both arms, non ocular SAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <description>Unrelated to study, crossed both arms, non ocular SAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Unrelated to study, crossed both arms, non ocular SAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>High Blood Pressure</sub_title>
                <description>Unrelated to study, crossed both arms, non ocular SAE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior Chamber Cell</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="36"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="35"/>
                <counts group_id="E3" events="62" subjects_affected="58" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Corneal Edema</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="36"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="35"/>
                <counts group_id="E3" events="43" subjects_affected="43" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Anterior Chamber flare</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Visual Disturbance</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Posterior Capsule Opacification</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vitreous Detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Increased Intraocular Pressure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Omid Khodai</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>(949) 521-7894</phone>
      <email>Omid.Khodai@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

